The role of perlecan in arterial injury and angiogenesis

被引：75

作者：

Segev, A ^{[1
]}

Nili, N ^{[1
]}

Strauss, BH ^{[1
]}

机构：

[1] Univ Toronto, St Michaels Hosp, Roy & Ann Foss Intervent Cardiol Res Program, Terrence Donnelly Heart Ctr,Div Cardiol, Toronto, ON M5B 1W8, Canada

来源：

CARDIOVASCULAR RESEARCH | 2004年 / 63卷 / 04期

关键词：

perlecan; heparan sulfate; arterial injury; angiogenesis;

D O I：

10.1016/j.cardiores.2004.03.028

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Perlecan is a large heparan sulfate proteoglycan (HSPG), which is a major component of the vessel wall. In relation to vascular biology, perlecan has been shown to be a potent inhibitor of smooth muscle cell (SMC) activity. In vivo experiments in animal models of arterial injury have shown that perlecan may inhibit thrombosis and intimal hyperplasia. On the other hand, perlecan has been shown to have opposing effects on endothelial cells (ECs), where it promotes in vitro and in vivo angiogenesis and plays an important role in mediating tumor growth. These diverse biological effects, or "the perlecan paradox", are discussed in this review paper. The properties of perlecan including inhibition of SMC activity and thrombosis while enhancing EC proliferation are ideal for the prevention of in-stent restenosis. Perlecan's pro-angiogenic effects may be used for the treatment of various ischemic diseases such as intractable coronary artery disease and peripheral vascular disease. (C) 2004 European Society of Cardiology. Published by Elsevier B.V. All rights reserved.

引用

页码：603 / 610

页数：8

共 100 条

[81] Paracrine or virus-mediated induction of decorin expression by endothelial cells contributes to tube formation and prevention of apoptosis in collagen lattices [J].